AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
XBiotech Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0081S8D48
1.93▼ 0.04 (-2.03%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.97
Day's Range
1.86 – 1.95
52-Week Range
1.86 – 3.44
Volume
121.7K
Avg Volume
55.1K
Share Statistics
Shares Outstanding
Employees
85
Exchange
XNAS
Listed
2015-04-15
Share count as of August 13, 2026

XBiotech Inc (XBIT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about XBiotech Inc (XBIT)
What is XBiotech Inc's Market Cap?
XBiotech Inc's Market Cap is $58.8M, based on as-reported figures from SEC (XBRL) filings.
What is XBiotech Inc's Enterprise Value?
XBiotech Inc's Enterprise Value is -$50.7M, based on as-reported figures from SEC (XBRL) filings.
What is XBiotech Inc's EV / EBITDA?
XBiotech Inc's EV / EBITDA is 1.1×, based on as-reported figures from SEC (XBRL) filings.
What is XBiotech Inc's Net Income (TTM)?
XBiotech Inc's Net Income (TTM) is -$45.1M, based on as-reported figures from SEC (XBRL) filings.
What is XBiotech Inc's EBITDA?
XBiotech Inc's EBITDA is -$46.8M, based on as-reported figures from SEC (XBRL) filings.
What is XBiotech Inc's Diluted EPS (TTM)?
XBiotech Inc's Diluted EPS (TTM) is -1.48, based on as-reported figures from SEC (XBRL) filings.
What is XBiotech Inc's Net Debt?
XBiotech Inc's Net Debt is -$109.5M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · XBITAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Research and development
General and administrative
Total operating expenses——
Loss from operations
Other (loss) income:
Interest income
Interest expense
Other (loss) income
Foreign exchange (loss) gain
Total other (loss) income
Loss before income taxes
Income tax expense
Net loss
Net loss per share—basic and diluted (in dollars per share)